Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Announces Proposed Public Offering
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…